References
- Mitsiades C S, Mitsiades N S, Munshi N C, Richardson P G, Anderson K C. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer 2006; 42: 1564–1573
- Podar K, Chauhan D, Anderson K C. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009; 23: 10–24
- Vande Broek I, Vanderkerken K, Van Camp B, Van Riet I. Extravasation and homing mechanisms in multiple myeloma. Clin Exp Metastasis 2008; 25: 325–334
- Alsayed Y, Ngo H, Runnels J, et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007; 109: 2708–2717
- Kim S-W, Kim H-Y, Lee H-J, Yun H-J, Kim S, Jo D-Y. Dexamethasone and hypoxia upregulate CXCR4 expression in myeloma cells. Leuk Lymphoma 2009; 50: 1163–1173
- Menu E, Asosingh K, Indraccolo S, et al. The involvement of stromal derived factor 1α in homing and progression of multiple myeloma in the 5TMM model. Haematologica 2006; 91: 605–612
- Nervi B, Ramirez P, Rettig M P, et al. Chemosensitization of AML following mobilization by the CXCR4 antagonist AMD3100. Blood, in press
- Oliveira A M, Maria D A, Metzger M, et al. Thalidomide treatment down-regulates SDF-1α and CXCR4 expression in multiple myeloma patients. Leuk Res 2009; 33: 970–973